About This Tool

The Padcev (enfortumab vedotin) Dosing Calculator is a clinical support tool designed for healthcare professionals to determine the appropriate dose and vial requirements based on patient weight. It simplifies the dosing process by incorporating the standard dose, subsequent dose reductions, and the maximum dose cap as specified in the official Prescribing Information.

Outputs

Upon entering the patient's weight and selecting the appropriate dose level, the calculator provides the following key outputs:

• Final Total Dose (mg): The calculated and rounded dose to be administered. For the standard 1.25 mg/kg dose, this is capped at a maximum of 125 mg.
• Total Volume to Withdraw (mL): The total volume of reconstituted solution (10 mg/mL) required to achieve the final dose.
• Vials Required: An optimized combination of 20 mg and 30 mg vials needed to prepare the dose, calculated to minimize drug wastage.

How to Use

Follow these simple steps to calculate the required dose:

1. Enter Patient Weight: Input the patient's current weight into the designated field.
2. Select Weight Units: Choose whether the entered weight is in kilograms (kg) or pounds (lbs).
3. Select Dose Level: Use the dropdown menu to select the appropriate dose based on the treatment plan: Standard Dose (1.25 mg/kg) or one of the three dose reduction levels (1.0, 0.75, or 0.5 mg/kg).

The results are calculated automatically and displayed in the output section. To start a new calculation, use the "Reset" button.

Dosing Overview

The recommended dose of Padcev is 1.25 mg/kg (up to a maximum of 125 mg) administered as a 30-minute intravenous infusion on Days 1, 8, and 15 of a 28-day cycle. Treatment should continue until disease progression or unacceptable toxicity. Dose modifications, including reductions or interruptions, may be necessary to manage adverse reactions. This calculator provides options for the three recommended dose reduction levels.

Switching Dose Levels

Switching to a lower dose level is a key strategy for managing adverse events. The Prescribing Information provides specific guidance on dose modifications for toxicities such as skin reactions, hyperglycemia, peripheral neuropathy, and ocular disorders. Once a dose has been reduced for an adverse reaction, it should not be re-escalated. If a patient requires a dose lower than the third reduction level (0.5 mg/kg), treatment should be discontinued.

Missed Dose

If a dose of Padcev is missed, it should be administered as soon as possible. The schedule of administration should be adjusted accordingly to maintain the treatment interval. Consult the full Prescribing Information for detailed guidance on managing treatment schedule interruptions.

Safety Alerts

Padcev has a boxed warning for serious skin reactions, including Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). Other significant warnings and precautions include hyperglycemia, pneumonitis/interstitial lung disease, peripheral neuropathy, ocular disorders, and embryo-fetal toxicity. Healthcare professionals must monitor patients closely for these adverse reactions. This tool does not replace clinical judgment; all dosing decisions must be made in the context of the patient's clinical status and the full safety information.

Frequently Asked Questions (FAQ)

• What is the maximum dose calculated for the standard 1.25 mg/kg regimen?
  The calculator automatically caps the dose at 125 mg for the standard 1.25 mg/kg level, even if the patient's weight would calculate to a higher dose.
• How does the calculator determine the combination of 20 mg and 30 mg vials?
  The algorithm determines the most efficient combination of vials to meet the final dose while minimizing the amount of wasted medication.
• What happens if I enter a very high or low patient weight?
  The tool will calculate the dose but may display a warning message prompting you to verify the weight, as it falls outside a typical clinical range.
• Does this calculator account for renal or hepatic impairment?
  No. This tool is for weight-based dosing only. Dose adjustments for patients with renal or hepatic impairment require specific clinical assessment and should be made according to the recommendations in the Prescribing Information.
• Why is the final dose rounded to a whole number?
  The calculated dose is rounded to the nearest whole milligram to ensure practical and accurate preparation and administration.
• What is the final concentration used for the volume calculation?
  The calculation assumes the recommended final concentration of 10 mg/mL after reconstitution.
• Can I use this calculator for pediatric patients?
  No. The safety and effectiveness of Padcev have not been established in pediatric patients. This tool is intended for adult patients only.
• What administration method is assumed by the tool?
  The tool's guidance is based on administration as a 30-minute intravenous infusion, not as an IV push or bolus.

References

This information is based on standard clinical practice and official product labeling. For complete and up-to-date guidance, always consult the primary sources.

• PADCEV (enfortumab vedotin-ejfv) Full Prescribing Information - U.S. Food and Drug Administration (FDA)
• PadcevHCP.com - Official Healthcare Professional Website by Astellas and Seagen
• Padcev European Public Assessment Report (EPAR) - European Medicines Agency (EMA)
• NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Bladder Cancer (requires free registration)